Thus, our results are similar to previous studies which showed that ALK and ROS1 fusion-positive early-stage NSCLC after curative resection had poorer RFS than ALK and ROS1 fusion-negative NSCLC.20, –22. The gene discussed is ALK; the disease is non-small cell lung carcinoma.